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For over 50 years it has been known that elevated high-density lipoprotein (HDL) cholesterol is preventative against the development of atherosclerosis 1 . Besides its role in cholesterol removal, HDL is also an antioxidant 2, 3 , it inhibits inflammation 4 and thrombosis 5 and also stimulates endothelial nitric oxide (NO) 6 and prostacyclin 7 release. In addition to these cardiovascular protective actions, recent research findings have elucidated the important role of HDL and its constitutive apoprotein components for glucose metabolism. HDL can lower blood glucose levels by mechanisms that include stimulation of insulin secretion from pancreatic -cells 8, 9 and activation of the AMPK signaling pathway in skeletal muscle 8, 10 . These findings have opened up
for an important area of investigation, especially given the increasing prevalence of metabolic disorders such as type 2 diabetes.
The recent work by Lehti an important t f f fin in indi di ing ng ng a a and nd d p p poi oi o nt n n s s to to to a a a d det et ete e erm rm rmin in inat at atio io ion n n of of of the he he f f fun un unct ct tio io iona na nal l l si si sign gn gnif if ific ic ican an nce ce ce o o on n n clinical trials investigating the long term effect of HDL raising agents are therefore needed as well as in-depth mechanistic trials. In regards to the latter, an unresolved area is how HDL affects tissue perfusion and consequently glucose availability via its effect on endothelium NO and prostacyclin formation 13 , especially given the present observation that HDL improves endurance performance. If the metabolic effect of chronic increases in HDL can be confirmed in humans, the therapeutic potential of HDL-raising agents to both prevent and treat cardiovascular disease and manage metabolic disorders in type 2 diabetes is promising.
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